Lai Wang
Chief Tech/Sci/R&D Officer en BEIGENE, LTD. .
Fortuna: 20 M $ al 31/03/2024
Perfil
El Sr. Lai Wang es director mundial de investigación y desarrollo en BeiGene Ltd.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
BEIGENE LTD
0.13% | 26/06/2023 | 1 658 215 ( 0.13% ) | 20 M $ | 31/03/2024 |
Cargos activos de Lai Wang
| Empresas | Cargo | Inicio |
|---|---|---|
| BEIGENE, LTD. | Chief Tech/Sci/R&D Officer | 01/04/2021 |
Antiguos cargos conocidos de Lai Wang.
| Empresas | Cargo | Fin |
|---|---|---|
Joyant Pharmaceuticals, Inc.
 Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Corporate Officer/Principal | - |
Formación de Lai Wang.
| Fudan University | Undergraduate Degree |
| University of Texas Health Science Center at Houston | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BEIGENE, LTD. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
- Bolsa de valores
- Insiders
- Lai Wang
